Print Page  |  Close Window

2015 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
07/28/15LabCorp Announces New Covance Leadership
Deborah Keller to succeed Joe Herring as Covance Drug Development CEO BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 28, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced that Deborah Keller will succeed Joseph Herring as Chief Executive Officer of Covance Drug Development (Covance). Mr. Herring will retire on July 31 after more than a decade as CEO. Ms. Keller joined Covance in 1987 and has held senior l... 
Printer Friendly Version
07/28/15Laboratory Corporation of America® Holdings Announces Record 2015 Second Quarter Results and Raises 2015 Adjusted EPS Guidance
Q2 Net revenue of $2.2 billion, up 46% over last year Q2 Diluted EPS of $1.64; Q2 Adjusted EPS of $2.09, up 14% over last year Q2 Free Cash Flow of $328 million, up 106% over last year 2015 Adjusted EPS guidance raised to $7.75 - $8.00 from $7.55 - $7.90 BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 28, 2015-- Laboratory Corporation of America® Holdings (LabCorp® or the “Company”) (NYSE... 
Printer Friendly Version
07/23/15Covance Opens Fit-for-Purpose Dallas Clinical Research Unit
LabCorp patient service center to be co-located in new facility to serve local patients and enhance volunteer recruitment DALLAS--(BUSINESS WIRE)--Jul. 23, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that Covance Drug Development has relocated its clinical research unit (CRU) in Dallas, TX, to a new, fit-for-purpose clinical research facility. The new unit, which opened earlier this month, has expan... 
Printer Friendly Version
07/01/15Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 1, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version
06/04/15LabCorp Expands Access to LabCorp AccuDraw® to Support Better Patient Care
BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 4, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (LH: NYSE) today announced the expanded availability of its proprietary specimen collection and handling software, LabCorp AccuDraw®, to all clients through its website at www.LabCorp.com. Combining on-screen visual cues with step-by-step tutorials, AccuDraw is an innovative tool designed to guide the health care professional who collects patie... 
Printer Friendly Version
06/02/15LabCorp is Scheduled to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 2, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the Goldman Sachs 36th Annual Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, June 9, 2015 at 5:00 PM (ET). A live audio webcast will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp® Labora... 
Printer Friendly Version
06/01/15Sysmex and LabCorp Announce a Strategic Collaboration for Blood-Based Molecular Testing Services and Products to Support the Development of Precision Medicine in Oncology
KOBE, Japan & BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 1, 2015-- Sysmex Corporation (TSE:6869) and Laboratory Corporation of America® Holdings (LabCorp®) (LH:NYSE) today announced a strategic collaboration focused on the development of blood-based molecular diagnostic tests to advance precision medicine in oncology. The collaboration combines Sysmex Inostics’ strength in the development of innovative blood-based diagnostic solutions with LabCorp's unp... 
Printer Friendly Version
05/18/15LabCorp Announces Full Portfolio of Hepatitis C Virus Drug Resistance Assays
Expanded testing services enable precision medicine by providing clinicians with information to select optimal treatment and characterize treatment failure BURLINGTON, N.C.--(BUSINESS WIRE)--May 18, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the launch of two new Hepatitis C Virus (HCV) drug resistance assays. The HCV NS5A and NS5B Drug Resistance Assays expand LabCorp’s portfolio of HCV resistance... 
Printer Friendly Version
05/12/15LabCorp is Scheduled to Present at the UBS Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--May 12, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the UBS Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, May 19, 2015 at 8:00 AM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp® L... 
Printer Friendly Version
05/06/15LabCorp is Scheduled to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--May 6, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the Bank of America Merrill Lynch 2015 Health Care Conference. LabCorp’s presentation is planned for Thursday, May 14, 2015 at 11:40 AM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About... 
Printer Friendly Version
04/27/15Laboratory Corporation of America® Holdings Announces 2015 First Quarter Results and Raises 2015 Adjusted EPS Guidance
Q1 Net revenue of $1.8 billion, up 24% over last year Q1 Diluted EPS of $0.01; Q1 Adjusted EPS of $1.73, up 15% over last year 2015 Adjusted EPS guidance raised to $7.55 - $7.90, compared to $6.80 in 2014 BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 27, 2015-- Laboratory Corporation of America® Holdings (LabCorp® or the “Company”) (NYSE: LH) today announced results for the quarter ended March 3... 
Printer Friendly Version
04/21/15Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers
BRCA Share™ is a novel public-private initiative designed to enhance the clarity and quality of patient testing MADISON, N.J. and PARIS and BURLINGTON, N.C., April 21, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Inserm, the French National Institute of Health and Medical Research institution, today launched BRCA Share™, a novel datashare initiative they co-founded to provide scientists and laboratory organizations ... 
Printer Friendly Version
04/09/15Bode Technology Supports Identification of Missing Persons in Cyprus Using DNA
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 9, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (LH: NYSE) today announced that its wholly-owned subsidiary Bode Cellmark Forensics (Bode Cellmark), a member of the LabCorp Specialty Testing Group, is cooperating with the Committee on Missing Persons (CMP) in Cyprus in its mission of exhumation, identification, and return of remains of missing persons in Cyprus. The CMP in Cyprus is a bi-com... 
Printer Friendly Version
04/01/15Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 1, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and Th... 
Printer Friendly Version
03/12/15LabCorp Presents New Findings on HIV-1 and HCV Antiviral Drug Resistance at the 2015 Conference on Retroviruses and Opportunistic Infections
State of the art genetic and cell-based assays enable comprehensive characterization of resistance to new drugs and new drug classes BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 12, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that Monogram Biosciences, Inc., a member of the LabCorp Specialty Testing Group, presented two new studies characterizing HIV-1 and HCV antiviral drug resistance at the 2015 Confer... 
Printer Friendly Version
03/11/15LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 11, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2015 to September 11, 2015, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading... 
Printer Friendly Version
03/04/15LabCorp Contributes to Clinical Research Collaborations Directed at Advancing Treatment of Breast Cancer and Viral Hepatitis
Studies Promote Personalized Medicine and Advance Public Health Initiatives BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 4, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today highlighted clinical research efforts in oncology and viral hepatitis that demonstrate its commitment to novel diagnostic capabilities and unique bioinformatics resources to enhance patient care in today’s rapidly evolving healthcare system. ... 
Printer Friendly Version
03/03/15LabCorp is Scheduled to Present at the Barclays Capital 2015 Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 3, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the Barclays Capital 2015 Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, March 10, 2015 at 8:30 AM (Eastern Time). A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and archived for replay. ... 
Printer Friendly Version
02/20/15Laboratory Corporation of America® Holdings Announces 2014 Fourth Quarter and Full Year Results and Provides 2015 Guidance
Strong Q4 volume drives sales of $1.5 billion Diluted Q4 EPS of $1.39; Adjusted Q4 EPS of $1.65 Q4 Operating Cash Flow of approximately $214 million Q4 Free Cash Flow of approximately $167 million Announces Project LaunchPad, its enterprise-wide business process improvement initiative 2015 Adjusted EPS guidance of $7.35 - $7.70, inclusive of Covance as of... 
Printer Friendly Version
02/19/15LabCorp Completes Acquisition of Covance
Combination Creates Leading Healthcare Diagnostics Company & End-to-End Solutions for Drug Development and Commercialization BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 19, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the completion of its acquisition of Covance Inc., following its entry into a definitive purchase agreement on November 2, 2014. At closing, the purchase consideration was valued at ... 
Printer Friendly Version
02/10/15LabCorp Launches New Patient-Centric Diabetes Report
BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 10, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the availability of a new Diabetes Patient Education report for type 2 diabetes patients that aligns with the American Diabetes Association (Association) “Standards of Medical Care in Diabetes – 2015,” which was published as a supplement to the January 2015 edition of the Association’s Diabetes Care journal. LabCorp’... 
Printer Friendly Version
01/21/15LabCorp Prices $500,000,000 in 2.625% Senior Notes Due 2020, $500,000,000 in 3.200% Senior Notes Due 2022, $1,000,000,000 in 3.600% Senior Notes Due 2025 and $900,000,000 in 4.700% Senior Notes Due 2045
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 21, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that it has priced its offering of $2.9 billion in senior notes. The offering consists of four tranches: $500,000,000 aggregate principal amount of 2.625% Senior Notes due 2020 (the “2020 Notes”), $500,000,000 aggregate principal amount of 3.200% Senior Notes due 2022 (the “2022 Notes”), $1,000,000,000 aggregate prin... 
Printer Friendly Version
01/21/15LabCorp Announces Proposed Sale of Senior Notes
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 21, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in four tranches with maturities of 5,7,10 and 30 years, respectively (the “Notes”). The Notes will be senior unsecured obligations and will rank equally with LabCorp’s existing and future senior unsecured debt. ... 
Printer Friendly Version
01/06/15LabCorp is Scheduled to Present at the 33rd Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 6, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. LabCorp’s presentation is planned for Tuesday, January 13, 2015 at 2:00 p.m. (PST). A live audio webcast of the presentation will be available via the Compa... 
Printer Friendly Version
01/02/15Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 2, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee (Trustee)... 
Printer Friendly Version